Evenity (romosozumab-aqqg) is a monthly injection for osteoporosis that both builds new bone and slows bone loss. In the United States it is approved for postmenopausal women at high risk of fracture, such as those who have already broken a bone or have very low bone density. It is given for a maximum of 12 monthly doses and then followed by another osteoporosis medicine to hold on to the gains. Because it carries a warning about heart attack and stroke, it is not suitable for everyone.
This guide explains how Evenity works, who is a good candidate, what treatment involves, its risks, and how it fits alongside other options for this common bone disease.
Osteoporosis in Brief
Osteoporosis is a condition in which bones lose density and their internal structure thins, making them fragile. Bone is constantly remodeled: cells called osteoclasts remove old bone, and osteoblasts lay down new bone. In osteoporosis, removal outpaces formation.
The condition is usually silent until a fracture occurs, most often in the spine, hip, or wrist. Spinal compression fractures can cause back pain, height loss, and a stooped posture. Hip fractures are the most serious, often leading to loss of independence.
Main Risk Factors
- Female sex and menopause, when falling estrogen speeds bone loss
- Older age and a family history of hip fracture
- Long-term corticosteroid use
- Low body weight, smoking, and heavy alcohol use
- Low calcium and vitamin D intake and physical inactivity
- Conditions such as rheumatoid arthritis, hyperthyroidism, and chronic kidney disease
How Evenity Works
Evenity is a monoclonal antibody that blocks sclerostin, a protein made by bone cells that acts as a natural brake on bone formation. With sclerostin blocked, osteoblasts build new bone more actively. At the same time, Evenity reduces bone resorption by osteoclasts.
This dual effect sets it apart. Most traditional drugs, such as bisphosphonates, only slow bone loss. Parathyroid hormone analogs, such as teriparatide, build bone but also increase resorption. Evenity pushes both sides of the balance in the right direction at once, which is why bone density rises quickly during the treatment year.
The bone-building effect fades after about a year of use, which is one reason treatment is limited to 12 doses.
How It Compares With Other Osteoporosis Drugs
| Drug class | Examples | Main action | How it is given |
|---|---|---|---|
| Sclerostin inhibitor | Romosozumab (Evenity) | Builds bone and reduces resorption | Monthly injection for 12 months |
| Bisphosphonates | Alendronate, risedronate, zoledronic acid | Slow resorption | Weekly or monthly tablets, or a yearly infusion |
| RANKL inhibitor | Denosumab | Slows resorption | Injection every 6 months |
| Parathyroid hormone analogs | Teriparatide, abaloparatide | Build bone | Daily self-injection for a limited period |
| SERMs | Raloxifene | Slow resorption, mainly in the spine | Daily tablet |
No single drug suits everyone. The choice depends on fracture history, bone density, kidney function, heart health, and how comfortable a patient is with injections.
Who Is a Candidate for Evenity?
Doctors consider Evenity for postmenopausal women at high or very high fracture risk. That typically includes women who have:
- Already had a fragility fracture, especially of the spine or hip
- Very low bone density on a DEXA scan
- Multiple risk factors that make a future fracture likely
- Continued to fracture, or not tolerated, other ways to treat osteoporosis
Evenity should not be started in anyone who has had a heart attack or stroke within the previous year, and it should not be used by people with uncorrected low blood calcium. For people with other cardiovascular risk factors, the decision involves weighing fracture risk against heart risk.
Diagnosis Before Treatment
An accurate diagnosis of osteoporosis comes before any treatment decision. The standard test is a dual-energy X-ray absorptiometry (DEXA) scan, which reports a T-score comparing your bone density with that of a healthy young adult.
| DEXA T-score | Category |
|---|---|
| -1.0 and above | Normal bone density |
| Between -1.0 and -2.5 | Low bone mass (osteopenia) |
| -2.5 and below | Osteoporosis |
| -2.5 and below with a fragility fracture | Severe (established) osteoporosis |
Blood tests check calcium, vitamin D, kidney function, and thyroid function to find secondary causes and make sure calcium is normal before starting Evenity.
What Treatment Involves
Evenity is given as 210 mg once a month, delivered as two injections under the skin, one after the other, by a healthcare professional. Treatment lasts 12 months. Patients are usually advised to take adequate calcium and vitamin D throughout, since supplement choices matter in management of osteoporosis.
What Comes Next
When Evenity stops, the new bone can be lost again without follow-up treatment. Guidelines therefore recommend moving straight to an antiresorptive drug, such as a bisphosphonate or denosumab, to lock in the gains. This sequence of building first and then maintaining is often called anabolic-first therapy.
Protecting Bones During the Treatment Year
Medication works best alongside daily habits. Weight-bearing and balance exercise, such as walking and tai chi, help strengthen bone and reduce falls. At home, removing loose rugs, improving lighting, and adding grab rails in the bathroom lower the chance of a fall. Stopping smoking and limiting alcohol also support bone health. A repeat DEXA scan after treatment shows how much density has been gained.
Side Effects and Safety
| Effect | What to know |
|---|---|
| Joint pain and headache | Among the more commonly reported side effects; usually mild |
| Injection site reactions | Redness or discomfort where the injection was given |
| Heart attack, stroke, cardiovascular death | Boxed warning; stop treatment and seek care if symptoms occur |
| Low blood calcium | Correct before starting; ensure calcium and vitamin D intake |
| Osteonecrosis of the jaw | Rare; tell your dentist and keep good oral hygiene |
| Atypical femur fracture | Rare; report new thigh or groin pain |
Key Takeaways
- Evenity blocks sclerostin, building bone and reducing bone loss at the same time.
- It is reserved for postmenopausal women at high fracture risk and is given monthly for 12 months.
- It is not used within a year of a heart attack or stroke.
- An antiresorptive drug should follow to keep the new bone.
- Exercise, fall prevention, calcium, and vitamin D remain part of every plan, including osteoporosis treatment for pain. For broader context, see our osteoporosis guide.
Frequently Asked Questions
How is Evenity different from Prolia or Fosamax?
Prolia (denosumab) and Fosamax (alendronate) mainly slow bone loss. Evenity also stimulates new bone formation, so bone density tends to rise faster. It is often used first in high-risk patients, followed by one of those drugs to maintain the benefit.
Why is Evenity only given for one year?
Its bone-building effect is strongest early and wanes over about 12 months. Treatment is limited to 12 doses, after which an antiresorptive drug protects the bone that was gained.
Can Evenity help with hip pain?
Evenity does not relieve pain directly; it lowers the chance of future fractures. Hip pain, especially at night, needs its own assessment, and our article on managing osteoporosis and hip pain covers the common causes.
Is Evenity safe if I have heart disease?
It should not be started within a year of a heart attack or stroke. For others with heart risk factors, your doctor will weigh fracture risk against cardiovascular risk and may suggest a different medicine.
